Fullerene compounds will help in the fight against lung cancer

October 22, 2019

The team of scientists from Skoltech Center for Energy Science and Technology, the Institute for Problems of Chemical Physics of Russian Academy of Sciences and National Taiwan University have discovered that fullerene compounds can effectively kill non-small-cell lung carcinoma cells and found out the mechanisms behind their anti-tumor activity.

Lung cancer is one of the most frequently experienced and severe forms of cancer. Every year more than a million of new cases are reported all over the world and 60% of them are fatal.

About 85% of all the lung cancer cases are non-small-cell lung carcinoma cases. This tumor type is difficult to treat because of the aggressive metastatic disease (spreading into other organs and tissues), frequent relapses (recurrence of the disease) and resistance to the standard anti-tumor drugs.

The existing chemotherapeutic drugs, cytostatic agents, suppress cancer cells development causing them to die, but at the same time, they are highly toxic for healthy cells which can lead to serious side effects.

A fullerene is a special form of carbon with molecules consisting of 60 carbon atoms, which look like a soccer ball. To make fullerenes soluble in water and biological media, polar functional groups are chemically attached to their surfaces.

A group of scientists from Skoltech headed by Professor P. A. Troshin in collaboration with a team from the National Taiwan University have found out that some of the fullerene compounds are toxic for non-small cell lung carcinoma cells and cause their death. At the same time, they are practically non-toxic for healthy cells which was shown both in cell models and in animal studies.

"The mechanisms leading to cancer cells death under the influence of fullerene derivatives have been unknown until recently. Our Taiwanese colleagues, while studying our compounds, succeeded in discovering that at least two mechanisms are involved: apoptosis and autophagy. It is interesting to know that it is the nature of the polar groups attached to the fullerene molecule that launches one or other mechanism in each particular case," says Olga Kraevaya, Skoltech PG student, co-author.

The anti-tumor activity of the fullerene derivatives has a great potential for the development of new effective medicinal products for treatment of non-small-cell lung carcinoma.
-end-
Research results were published in Journal of Medicinal Chemistry.

Skolkovo Institute of Science and Technology (Skoltech)

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.